Part II — Full Reading Version: Journal Print Advertisements

Part II: Journal Print Advertisements

Part II covers advertising placed in professional journals aimed at healthcare professionals — that is, in print. Conference program booklets, company-published periodicals, and even cases where such material is later reposted to the Web all fall within the discipline described here. Where Part I governed "the material itself" through the product information summary, Part II governs "a printed page placed in public view as an advertisement." The guide's organizing idea — that media with different characters require different conventions — applies here just as plainly.

01Why journal advertising stands as its own part

A product information summary assumes that a healthcare professional actively requests it and reads it with deliberation. A journal advertisement is not like that. It enters the eye in the motion of a turning page, in the gaps between following academic papers. When the reader's posture differs, the conventions demanded of the writer differ too. The guide made Part II independent precisely because it accounts for this difference in how the material is received.

The foreword positioned the product information summary and similar materials as a complement to the package insert. The single word "complement" carries the meaning that no expression may exceed the original — the approved content. Journal advertising is no exception. If anything, because the advertising format has the power to form an impression in an instant, the danger of straying beyond the scope of approval is higher. That is exactly why a separate chapter is set out, lining up the safeguards specific to print advertising.

02Three types by content carried

Part II broadly divides advertising into three types according to what the page carries. Even under the single phrase "journal advertising," the breadth of information that may be shown differs entirely.

This three-way split has a purpose. The more information increases, the more room there is to create misunderstanding. So ordinary advertising, rich in information, bears the most mandatory entries, while product-name advertising, which carries almost no information, finds its discipline in "carrying none." Editorial-style advertising, wearing the face of an article, makes its key point the device that does not hide that it is advertising — the clear naming of the providing company. The details of each are developed in the child pages.

Ordinary advertising — not dropping the mandatory on a narrow page

In ordinary advertising, the following become mandatory: the name (brand and generic), therapeutic class name, regulatory category, indications (including related precautions), dosage and administration (likewise), precautionary information including warnings and contraindications, whether listed in the drug price standard, the marketing authorization holder's name, where applicable notes on insurance coverage and approval conditions, and the date of preparation. Text is six points or larger; warnings and contraindications are made conspicuous in gothic typeface at eight points or larger.

Product-name advertising — the discipline of "not carrying"

Product-name advertising is advertising centered on the product name. It carries neither indications nor dosage, nor any catchphrase that suggests efficacy or safety. Product logos and dosage-form photographs may be used, but combining them to imply efficacy or dosage is not permitted. At first glance it looks confining, but it is a type built on the resolve that "if no information is carried, no misunderstanding arises." For that very reason, provisions line up to close the loopholes — hinting at efficacy through photographs or figures.

Editorial-style advertising — not hiding that it is advertising

Because editorial-style advertising takes the form of an article or information, the reader finds it hard to notice it is advertising. So the providing company's name must be clearly written on the article page. Even in the guise of a roundtable or interview, data provided by a physician but not published in a paper, or data presented at a conference, are not carried. Impressions or sentiments of treatment experience avoid assertion and make no emphasis or guarantee. Even in the form of a statement, one may not suggest or recommend efficacy beyond approval. The loophole of "borrowing someone's mouth to step beyond the frame of approval" is one the guide clearly closes.

03How the discipline of science works on the page

The scientific conventions the foreword set out — the hierarchy of evidence, the difference in weight between pre-specified and post-hoc, that a significant difference is not clinical significance itself, the asymmetric duty to disclose safety even when unfavorable — operate consistently in journal advertising too.

Take significance testing of safety. A way of showing that places a significance test demonstrating no difference from placebo so as to create the impression that "adverse reactions are few" is not permitted in ordinary advertising. This is an expression of the design principle that closes off "true but misleading." Even if the test figure itself is fact, if the way it is placed forms a false image in the reader's mind, it is treated the same as falsehood.

04Governing the unwritten domain by higher norms

The foreword made clear that the guide is a set of basic matters, not a complete enumeration, and that materials outside its provisions remain subject to the Pharmaceutical and Medical Device Act, the Standards for Fair Advertising, the guidelines for sales information provision activities, and the JPMA Code. When one meets a page that does not fit precisely into the three types of Part II, the answer is not "no provision, therefore free." Against the purpose of the advertisement — how far and in what way to convey the product's efficacy and safety — one returns to the spirit of the nearest type and to the higher norms to judge. The foreword's spirit of not turning a manual into an answer key becomes the operating rule here as well.

→ Source page: Part II: Journal Print Advertisements

Chapter 1: Standard Advertisements

The "general advertisement," placed at the head of Part II, is the form of journal (print) advertising that allows you to say the most. Beyond the product name and a catchphrase, it can carry the indication, the dosage and administration, and the advertising product information (DI)—data and all. But breadth of expression is also breadth of room to mislead. So this chapter, which reads on its surface as a list of permissions for what you may include, is better read as a set of rules about where to stop precisely because so much is permitted.

01What a general advertisement is—the place of the "ad that can speak"

Journal advertisements split into three kinds by what they carry: the name-only advertisement that stays with the product name, the editorial-style advertisement built like an article, and this general advertisement. The general advertisement comes with advertising DI and may carry features, data, and a catchphrase. Among the three types it has the widest expressive latitude.

Yet latitude is, by the spirit of the foreword, a property to watch. The foreword positions the package insert as the basis of proper-use information, with the product information summary and other materials serving to "supplement" it. Advertising is no exception. The original is the approved content; the advertisement cannot exceed the scope of approval by a single character. More to say does not widen what may be said—and the more there is to say, the easier it becomes to spill past the approved scope.

Why mandatory items are imposed on the general advertisement

The general advertisement has items that must appear. The name, comprising both brand and generic names; the therapeutic classification name; the regulatory category; the indication (with its related cautions); the dosage and administration (likewise with related cautions); the precautionary information including warnings and contraindications; whether the drug is listed in the drug tariff; the marketing authorization holder's name (with the contact for literature requests and inquiries); where applicable, notes on insurance benefits and approval conditions; and the date of preparation. These are not "include them if you can" items—they are the skeleton without which the advertisement does not stand as one.

The reason mandatory items exist lies in the foreword's twofold duty: to convey accurately and not to mislead. An advertisement that speaks loudly of effect while omitting who may use it and what dangers it carries leaves a false picture even when it tells no lie. Mandatory items embed, on the advertising side and as an obligation set in advance, the minimum set of information a reader needs to reach a safe prescribing judgment.

02The discipline of type size—how it looks is part of the information

Body text in a general advertisement is set at 6 points or larger. Warnings and contraindications go further: gothic (bold) type, 8 points or larger, set to stand out. Pinning the lower bound to a number looks like over-fine regulation, but a clear idea sits behind it.

Information changes meaning not only by whether it appears but by how it appears. Raise the effect in a large headline and bury the contraindication in a footnote too small to read, and though both are formally present, only the effect stays in the reader's mind. This is the classic "true but misleading." Once the foreword set "do not mislead" as a duty independent of, and alongside, the prohibition on falsehood, the discipline of appearance becomes its very implementation. Specifying a minimum size and even a typeface for warnings and contraindications is a structural defense against the heaviest safety information vanishing from view.

03What must not appear—reference information, competitor comparisons, case reports

The general advertisement names things that clearly must not appear. First, "reference information." Second, comparative trials against other companies' products. Third, case presentations. Each can be handled under defined conditions in deeper, broader materials (the product information summary or presentation content), but not in the limited space of an advertisement. Why the advertisement alone is stricter follows from the nature of each.

Why reference information is excluded

Reference information means results obtained secondarily within the approved scope—quality of life, daily activity, pharmacological actions whose link to the indication is unclear. In a product information summary these may be carried if labeled and segregated as "reference information," but an advertisement carries none of it. An advertisement is received quickly, and a segregation label works poorly there. If information that is not the core of approval appears seamlessly next to the indication, it leads readers to misperceive the scope of approval. So the advertisement does not bring it in at all.

Why competitor-comparison trials are excluded

Put a comparative trial against another company's product into an advertisement, and the medium's nature makes the temptation to excerpt only the winning part nearly unavoidable. One of the design pillars the foreword supports is the ban on disparagement and on selective, contrived extraction. In an advertisement that cannot fully supply the comparison's context, raising a head-to-head comparison drifts toward making the rival look unfairly low. The line—an advertisement simply does not take up this subject—prevents the accident in advance.

Why case presentations are excluded

A case presentation always carries the danger that one vivid course shapes the picture of the whole drug. Generalizing the impression of a few cases runs head-on against the idea of the evidence hierarchy. A case report sits low in that hierarchy, and speaking of effect from a single case has no scientific support. The advertisement is the medium where this impression-shaping force works most easily, so case presentations are kept out.

04The ban on exaggeration and guarantees—why "few side effects" cannot be written

A general advertisement must make no superlative claims, no guarantees, and no safety emphasis such as "few side effects." This is not a question of taste but a prohibition rooted in the logic of statistics and approval.

The flat assertion "few side effects" leaves only reassurance, without ever showing few compared to what. Even if a comparative trial showed a difference, statistical significance does not by itself mean clinical significance. Conversely, the absence of a significant difference does not prove "equivalence." A safety claim properly stands only when it carries these subtle distinctions—yet the single word "few" skips all of them. So categorical safety emphasis is not allowed.

Superlatives and guarantees follow the same reasoning. "Most effective" or "certain to work" become assertions beyond what evidence can show. What a clinical trial can speak of is an effect observed at some probability under certain conditions—not the absolute or the supreme. When an advertisement crosses that boundary, it brings a promise science cannot support into the clinical setting.

05How to build the page—portraits, catchphrases, regulatory display

The general advertisement sets several concrete brakes on the very construction of the page. As fifth-level detail, it is worth expanding these carefully.

Do not make portrait photos the main element

Do not build an advertisement around portrait photographs of people. Introducing the participants of a roundtable is an exception, but otherwise putting the photo of a celebrity or physician front and center is not permitted. The persuasive force of a photo creates the impression that "an authority recommends this," independent of what the data contain. This stages trust through appearance rather than the quality of information, against the duty not to mislead.

Do not repurpose the therapeutic classification name as a catchphrase

Detaching the therapeutic classification name from the product name and using it like a catchphrase is not permitted. The classification name is information that locates the product objectively; it is not a striking slogan to set walking on its own. Held up large and apart from the product name, it breeds the misperception that the classification is some intrinsic merit of the product.

Display for prescription drugs

For prescription drugs, state the regulatory category "prescription drug" explicitly, and alongside it the note "Caution—use only under the prescription of a physician or the like." This display fixes the entry to distribution and use at the physician's judgment, ruling out any impression that anyone may use it.

Full indications in specialty-field advertisements

Even an advertisement aimed at a specific specialty field must not stop at that field's indication alone. In addition to the indication for that field, state the full text of the other approved indications as well. Showing only a convenient slice to specialists would either misperceive the approved scope as narrower than it is, or unduly emphasize a particular use. Not omitting the whole picture of approval is the honesty required here.

06Rereading the general advertisement through the foreword's spirit

The rules so far look like separate prohibitions, yet they converge on the few pillars the foreword raised. Do not exceed the scope of approval (state indication and dosage accurately, with related cautions, and the full indications even in a specialty field). Do not mislead (the size floor, the limit on portraits, the discipline over catchphrases). Disclose safety information even when unfavorable (mandatory warnings and contraindications with their size, and the ban on safety emphasis). And do not bring context-dependent information into a medium that resists adding context (the exclusion of reference information, competitor comparisons, and case presentations).

The general advertisement can say the most among the three types. For that very reason, it is the form that must most consciously keep apart what it can say from what it may say. Permitted freedom holds only in a set with the line at which to stop.

→ Source page: Chapter 1: Standard Advertisements

Chapter 2: Name-Only Advertisements

The brand-name advertisement is the most reticent format among the ads aimed at healthcare professionals in print journals. Showing the product's name is, in itself, the whole purpose. No efficacy, no dosage, no data, no catchphrase belongs here. At first glance this looks like a cramped set of rules, but that very silence is the purest embodiment of the spirit the creation guide set out in its foreword. Why is only the name allowed? Trace the reason and you arrive at the foundation: that the original document for proper-use information is the electronic package insert.

01What a brand-name ad is — an ad that only announces a name

If a standard advertisement is one that "carries advertising DI and may present features, data, and catchphrases," the brand-name ad sits at the opposite pole. It centers on the product name and is accompanied by no information whatsoever about efficacy or safety. All the reader learns is the external fact that a product by this name exists, which company markets it, and whether it appears in the price standard.

The items that may be listed are confined to these five.

• Name (brand name and generic name)
• Therapeutic classification name
• Regulatory category
• Whether listed in the NHI price standard
• Marketing-authorization holder's name

A standard ad is required to carry efficacy and indications, dosage and administration, and even the precautions information including warnings and contraindications. The brand-name ad exists by not carrying those. An advertisement defined by subtraction, you might say.

02Why no efficacy or safety information at all

This is the heart of the format. Write even a single line of efficacy and the guide immediately triggers a separate set of duties: if you state efficacy you must give safety equal or larger type, you must show the supporting data within the material, you must attach the source, you must not exceed the approved scope by one character. A whole array of heavy constraints rises at once. The brand-name ad severs this chain at the start, by never speaking of efficacy in the first place.

The foreword stated plainly that product information summaries and the like sit in a position that "complements" the electronic package insert. The original is the approved content itself, and a complement cannot exceed the original's scope. The brand-name ad, showing only a name, observes this subordinate relationship in the most straightforward way. Present efficacy in fragments and the reader cannot verify, from the ad alone, which part of the original it corresponds to. Information whose verifiability cannot be secured is simply not carried. That is the logic of the brand-name ad.

Sealing off "true but misleading" at the most upstream point

One implication of the foreword is that the duty "not to lie" and the duty "not to mislead" are distinct. Even without writing a falsehood, if presentation alone forms a wrong impression, that is a violation. The brand-name ad satisfies this duty structurally, by blocking at the entrance the very information that creates room for misunderstanding. Say nothing, and there is no way to mislead. It is a preventive design, erring to the safe side.

03Handling of visuals and catchphrases

The same brake applies not only to text but to pictures and photographs. Efficacy may not be turned into an illustration. A product photo bearing efficacy or dosage may not be used. In other words, you cannot detour around what text forbids by using images. Change the medium of expression, and if the conveyed substance reaches efficacy or safety, it is the same violation.

Logos and photos can become a violation through "the art of combination"

The product logo, product photo, and dosage-form photo may each be carried on their own. The problem is their combination. Arrange several elements so as to hint at efficacy or dosage, or to emphasize a particular use, and the whole becomes a violation even though each element is lawful in isolation. Placing, beside a dosage-form photo, an image that evokes a certain scene so as to suggest the use, is one such composition. Note that judgment turns not on the legality of the elements but on the impression they synthesize.

04The required note — a path to the electronic package insert

A brand-name ad carries no efficacy and no precautions. Yet that differs from "hiding information." A clear path to the original — the electronic package insert — must be left in place. Concretely, a note to the effect of "for efficacy, dosage, warnings, contraindications and the like, refer to the electronic package insert" must be set in type of 8 points or larger.

This note is also the brand-name ad's own self-definition. It tells the reader, "only a name is written here; the information needed for a decision is in the original," and at the foot of the ad it reaffirms the foreword's structure in which product information summaries complement the electronic package insert. The lower bound on type size is set because a path that cannot be seen does not function as a path. The guide's habit of specifying even how things appear runs through here as well.

→ Source page: Chapter 2: Name-Only Advertisements

Chapter 3: Advertorial Formats

01What an article-style ad is — "advertising wearing the face of an article"

An article-style advertisement appears in a professional journal in the form of an article or a piece of editorial information, yet it is, in substance, advertising. Tie-up articles produced jointly by a pharmaceutical company and an editorial team belong here, as do pieces shaped as roundtable transcripts or interviews. Readers — healthcare professionals — habitually read articles as neutral information and advertisements as the seller's claims. An article-style ad sits right on the seam between those two reading modes. That is exactly why it carries a structural risk: the reader may take an advertisement for a neutral article without realizing it.

Part II of the Creation Guide covers advertising in professional journals (print) and sorts it, by the richness of its content, into ordinary advertising, name-only advertising, and article-style advertising. The article-style form looks like the freest of the three, but greater freedom means greater room to mislead. What the Creation Guide repeatedly demands in this chapter comes down to one thing: make the reader aware that this is an advertisement, and do not use the guise of an article to slip past the rules that govern advertising.

02Touch efficacy or safety, and the ordinary-ad rules ride along intact

If an article-style ad deals with content bearing on a product's efficacy or safety, it must satisfy every item required of ordinary advertising. The article format is no excuse to drop the mandatory elements — name, regulatory classification, indications, dosage and administration, precautionary information including warnings and contraindications, the marketing authorization holder's name, and the date of preparation.

The logic is plain. To the reader, whether the information arrives dressed as an article or as an advertisement does not change the premises needed to judge it. Once efficacy or safety is discussed, the piece is conveying product information, and such conveyance must come with the facts of approval and the handholds for verification. The vessel of an "article" does not dilute the responsibility imposed on product information.

State the sponsoring company's name on the article page

An article-style ad must clearly carry the name of the company providing it on the article's own page. This is not a formal byline but the central device for preventing misunderstanding. Only when the reader knows who paid for the piece and in whose interest it was written can they discount its claims appropriately. An article-style ad that hides its sponsor becomes advertising disguised as neutrality — the textbook case of "true but misleading" that the foreword guards against most.

Warnings and contraindications need not sit on the opening page

Whereas a comprehensive product information summary must place warnings and contraindications in a prominent spot on its cover, an article-style ad may position them somewhere other than the opening page. This does not license treating safety information lightly. It is a reading-across that recognizes a practical reality: the flow of an article does not sit easily with a statutory boxed notice forced onto the very first page. In exchange for freedom of placement, the content itself may not be omitted. As media evolve from print into digital and into the article-style form, the principle of always delivering safety information stays fixed; only the manner of presentation bends to the medium — one instance of the foreword's "homework of reading the conventions of print across into digital."

03Data must be accurate and scientifically grounded — nothing less

The data carried in an article-style ad must be accurate, with scientific backing and reliability. The soft vessel of an article makes it easy to let impressions and anecdotal data slip in. But however soft the vessel, the evidentiary standard for its contents is hard. The premise is that the piece rests on quality-checked grounds: peer-reviewed original papers, or materials evaluated during the approval review.

Safeguards specific to roundtables and interviews

Roundtable transcripts and interview pieces — the very archetype of the article-style ad — open loopholes precisely because they take the form of spoken remarks. The Guide closes them concretely.

• Do not carry unpublished data. Data a participating physician supplies privately, or data that exists only as a conference presentation and has not been written up as a paper, must not appear, even in a roundtable or interview. The point is to bar numbers that have not passed peer review from entering an article through a physician's mouth.
• Do not assert impressions from treatment experience. Anecdotes such as "it worked well when I used it" must avoid assertion and must not be turned into emphasis or a guarantee of efficacy. A personal impression, even if it is a fact for that physician, is no proof of a drug's efficacy in general.
• Even within a quotation, do not suggest or recommend off-label efficacy. Indirect speech — a remark inside an article — lends the appearance that this is not the company's own claim. But whoever's mouth it comes from, suggesting an indication beyond the approved range is off-label promotion, and it is not allowed.

What these share is the intent to block the excuse that "it was a remark, so the company is not responsible." Passing through the format of an article or the mouth of a third party, information that misleads still misleads. The single word "complement" from the foreword — that product information summaries sit below the package insert and may not exceed the approved range by a single character — reaches article-style ads that quote remarks just as fully.

04Handling comparison and case reports — neither disparage nor self-promote

When an article-style ad takes up clinical comparative trials or case reports, it must lean neither toward denigrating competitors nor toward exalting its own product. Comparison is the act of laying out facts, not of pronouncing superiority. Because the narrative freedom of an article tends to blur this line, the Guide sets concrete prohibitions.

Why significance-test results on safety are excluded

An article-style ad does not carry the results of significance testing on safety. This is a safeguard grounded in what statistics actually mean. The absence of a significant difference does not prove equivalence, and the presence of one does not necessarily indicate a clinically meaningful difference. When this misreading occurs in the domain of safety, it can steer the reader toward seeing harm as small, or a comparator as dangerous. Raw facts — event names, case counts, incidence rates — may be shown, but bringing a test's conclusion to bear on safety edges toward impression management dressed in statistics.

05Do not make product-name articles aimed at the general public

An article that names a product must not be created for the general public (non-professionals, including patients). Such an article, however much it takes the form of an article, is regarded in substance as advertising for a specific product. Prescription drugs are used on the premise of healthcare professionals' specialist judgment. Delivering a specific product name to the general public in the form of an article becomes an attempt to move the entry point of prescribing from the patient's side, and it runs against the cardinal principle that advertising of prescription drugs targets healthcare professionals.

This provision runs along a single line with Part III's disease-explanation materials and patient-facing materials, which require staying within an explanation of the disease and not steering toward a specific drug. When facing patients, the moment a product name appears, "neutral provision of information" mutates into "promotion of a specific drug." In the article-style form — which already stands on the seam between advertising and article — that mutation is even harder to see. So the Guide shuts the entry point itself: naming a product to the general public.

→ Source page: Chapter 3: Advertorial Formats